Patient-derived xenografts for individualized care in advanced sarcoma

Stebbing, J., Paz, K., Schwartz, G. K., Wexler, L. H., Maki, R., Pollock, R. E., Morris, R., Cohen, R., Shankar, A., Blackman, G., Harding, V., Vasquez, D., Krell, J., Zacharoulis, S., Ciznadija, D., Katz, A., Sidransky, D. (July 2014) Patient-derived xenografts for individualized care in advanced sarcoma. Cancer, 120 (13). pp. 2006-15. ISSN 1097-0142 (Electronic)0008-543X (Linking)

URL: https://www.ncbi.nlm.nih.gov/pubmed/24705963
DOI: 10.1002/cncr.28696

Abstract

BACKGROUND: Patients with advanced, metastatic sarcoma have a poor prognosis, and the overall benefit from the few standard-of-care therapeutics available is small. The rarity of this tumor, combined with the wide range of subtypes, leads to difficulties in conducting clinical trials. The authors previously reported the outcome of patients with a variety of common solid tumors who received treatment with drug regimens that were first tested in patient-derived xenografts using a proprietary method ("TumorGrafts"). METHODS: Tumors resected from 29 patients with sarcoma were implanted into immunodeficient mice to identify drug targets and drugs for clinical use. The results of drug sensitivity testing in the TumorGrafts were used to personalize cancer treatment. RESULTS: Of 29 implanted tumors, 22 (76%) successfully engrafted, permitting the identification of treatment regimens for these patients. Although 6 patients died before the completion of TumorGraft testing, a correlation between TumorGraft results and clinical outcome was observed in 13 of 16 (81%) of the remaining individuals. No patients progressed during the TumorGraft-predicted therapy. CONCLUSIONS: The current data support the use of the personalized TumorGraft model as an investigational platform for therapeutic decision-making that can guide treatment for rare tumors such as sarcomas. A randomized phase 3 trial versus physician's choice is warranted.

Item Type: Paper
Uncontrolled Keywords: Aged Animals Child Chondrosarcoma/surgery Female *Heterografts Humans Leiomyosarcoma/surgery Liposarcoma/surgery Male Mice Mice, SCID Middle Aged Myxoma/surgery Precision Medicine/*methods Rhabdomyosarcoma/surgery Sarcoma/genetics/pathology/secondary/*surgery Sarcoma, Ewing/surgery Sarcoma, Synovial/surgery *Transplantation, Heterologous Treatment Outcome TumorGraft biomarker chemotherapy prediction response sarcoma trial
Subjects: diseases & disorders > cancer
diseases & disorders > cancer > drugs and therapies > chemotherapy
organism description > animal > mammal > rodent > mouse
therapies > personalised therapy
diseases & disorders > cancer > cancer types > sarcoma
CSHL Authors:
Communities: CSHL labs > Maki lab
Depositing User: Matt Covey
Date: 1 July 2014
Date Deposited: 20 Oct 2016 14:34
Last Modified: 20 Oct 2016 14:34
PMCID: PMC4298787
Related URLs:
URI: http://repository.cshl.edu/id/eprint/33764

Actions (login required)

Administrator's edit/view item Administrator's edit/view item
CSHL HomeAbout CSHLResearchEducationNews & FeaturesCampus & Public EventsCareersGiving